afabicin (Debio 1450)
Bone and joint infections
afabicin (Debio 1450) is a new antibiotic benefiting from both oral and IV formulations. It is a highly potent, staphylococcus-selective antibiotic with a low propensity to emergence of resistance. This first-in-class FabI inhibitor retains its activity on staphylococci strains resistant to antibiotics currently in clinical use including beta lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, will now be studied in Bone & Joint infections (BJIs) caused by staphylococci.
April 8, 2016
Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID
April 11, 2016
Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…